Development of a CO2-bicarbonate combined membrane capture system for accessible treatment of acute respiratory failure
Ended Project Grant Awarded Last action
- Award ID
- R43HL158345
- Recipient
-
X-Cor Therapeutics Inc. UEI C8ALEDEUU658
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $293,107
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- Framingham, MA 01702, USA
Award details come from USAspending.gov.
Description
- Abstract
- X-COR therapeutics is creating the first extracorporeal CO2 removal (ECCO2R) device that uses dialysis-like approaches to accessibly treat hypercapnic respiratory failure (HRF) patients. HRF is a devastating consequence of critical lung disease caused by chronic obstructive pulmonary disease (COPD) and other respiratory disorders including acute respiratory distress syndrome (ARDS), a common complication of covid-19. The current standard of care for severe disease is invasive mechanical ventilation, which results in a ~30% mortality rate and increased susceptibility to ARDS. While use of protective ventilatory strategies reduces mortality, resultant hypercapnia from protective ventilation resembles diseases like COPD. In both cases, impaired ventilation causes increased carbon dioxide (CO2) levels that lead to acidosis, coma, and death. For patients with hypercapnia, extracorporeal technologies that deliver oxygen and remove gaseous CO2 (e.g. ecmo) present possible alternatives but are highly invasive and costly. They require high blood flow rates (>1 L/min) and large-bore cannula only deployable in specialized facilities. Here, we propose investigating a hybrid device that resembles a hemodialysis-like blood filtration cartridge that contains a novel configuration of two filtration fibers for bicarbonate dialysis and gaseous CO2 capture. High efficiency CO2 removal allows a low blood rate of
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$14 | |
| Original award | $293,121 |
Quick answers
Who received award R43HL158345?
R43HL158345 was awarded to X-Cor Therapeutics Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 17, 2021.
How much is award R43HL158345 worth?
$293,107 has been obligated on R43HL158345.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award